819 related articles for article (PubMed ID: 8579962)
1. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
2. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
4. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study.
Chen HK; Ke HZ; Jee WS; Ma YF; Pirie CM; Simmons HA; Thompson DD
J Bone Miner Res; 1995 Aug; 10(8):1256-62. PubMed ID: 8585430
[TBL] [Abstract][Full Text] [Related]
5. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Pirie CM; Simmons HA; Chidsey-Frink KL; Chen HK; Jee WS; Thompson DD
Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783
[TBL] [Abstract][Full Text] [Related]
6. Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats.
Chen HK; Ke HZ; Lin CH; Ma YF; Qi H; Crawford DT; Pirie CM; Simmons HA; Jee WS; Thompson DD
Bone; 1995 Oct; 17(4 Suppl):175S-179S. PubMed ID: 8579914
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.
Cui L; Wu T; Liu YY; Deng YF; Ai CM; Chen HQ
Acta Pharmacol Sin; 2004 May; 25(5):678-84. PubMed ID: 15132837
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 prevents ovariectomy-induced cancellous bone loss in rats.
Ke HZ; Li M; Jee WS
Bone Miner; 1992 Oct; 19(1):45-62. PubMed ID: 1422305
[TBL] [Abstract][Full Text] [Related]
9. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
[TBL] [Abstract][Full Text] [Related]
10. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
11. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
Iwaniec UT; Yuan D; Power RA; Wronski TJ
J Bone Miner Res; 2006 Jul; 21(7):1068-74. PubMed ID: 16813527
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
14. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
16. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Boyce RW; Wronski TJ; Ebert DC; Stevens ML; Paddock CL; Youngs TA; Gundersen HJ
Bone; 1995 Feb; 16(2):209-13. PubMed ID: 7756049
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic effects of 1,24,25-trihydroxyvitamin D3 on ovariectomy-induced cancellous bone loss in the rat.
Erben RG; Bante U; Birner H; Stangassinger M
Calcif Tissue Int; 1997 May; 60(5):434-40. PubMed ID: 9115161
[TBL] [Abstract][Full Text] [Related]
18. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats.
Erben RG; Weiser H; Sinowatz F; Rambeck WA; Zucker H
Calcif Tissue Int; 1992 Mar; 50(3):228-36. PubMed ID: 1617497
[TBL] [Abstract][Full Text] [Related]
20. Short-term prophylaxis against estrogen depletion-induced bone loss with calcitriol does not provide long-term beneficial effects on cancellous bone mass or structure in ovariectomized rats.
Erben RG; Bromm S; Stangassinger M
Osteoporos Int; 1998; 8(1):82-91. PubMed ID: 9692082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
